ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- T-cell subsets inClinical & translational immunology · 2025Review
- IFN-γ Limits Immunopathogenesis but Delays Fungal Clearance during Pneumocystis Pneumonia.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Immune Response inJournal of fungi (Basel, Switzerland) · 2021Review
- Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia.BMC infectious diseases · 2021Article
- Immune reconstitution inflammatory syndrome associated withThe Journal of international medical research · 2020Article
- Intrinsic Programming of Alveolar Macrophages for Protective Antifungal Innate Immunity AgainstFrontiers in immunology · 2018Article
- Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.Ocular immunology and inflammation · 2016Review
- Thymidine-Dependent Staphylococcus aureus Small-Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have Increased Fitness during SXT Challenge.Antimicrobial agents and chemotherapy · 2015Article
- Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall.Infection and immunity · 2015Article
- Pathological and protective immunity to Pneumocystis infection.Seminars in immunopathology · 2015Review
- Dectin immunoadhesins and pneumocystis pneumonia.Infection and immunity · 2013Article
- Article
- All-trans retinoic acid in combination with primaquine clears pneumocystis infection.PloS one · 2013Article
- Immune Modulation as Adjunctive Therapy for Pneumocystis pneumonia.Interdisciplinary perspectives on infectious diseases · 2011Article
- Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.PLoS pathogens · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The T cell-mediated immune response elicited by Pneumocystis plays a key role in pulmonary damage and dysfunction during Pneumocystis carinii pneumonia (PcP). Mice depleted of CD4(+) and CD8(+) T cells prior to infection are markedly protected from PcP-related respiratory deficit and death, despite progressive lung infection. However, the therapeutic effectiveness of Ab-mediated disruption of T cell function in mice already displaying clinical symptoms of disease has not been determined. Therefore, a murine model of PcP-related immune reconstitution inflammatory syndrome was used to assess whether Ab to the pan-T cell molecule CD3 is effective for reducing the severity of PcP when administered after the onset of disease. Mice that received anti-CD3 Ab exhibited a rapid and dramatic halt in the PcP-associated pulmonary function decline within 1 week after treatment, and a striking enhancement of survival rate compared with mice receiving the control Ab. Physiologic improvement in anti-CD3 treated mice was associated with a significant reduction in the number of CD4(+) and CD8(+) T cells recovered in lung lavage fluid. This effectiveness of anti-CD3 was noted whether the mice also received antibiotic therapy with trimethoprim-sulfamethoxazole. These data suggest that monoclonal Ab-mediated disruption of T cell function may represent a specific and effective adjunctive therapy to rapidly reverse the ongoing pathologic immune response occurring during active PcP. Thus, the anti-human CD3 monoclonal Ab OKT3, which is already in clinical use, has the potential to be developed as an adjunctive therapy for PcP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.